Abstract:
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
Abstract:
There is provided a polymerizable composition, by which discoloration or alignment defects are less likely to occur when a filmy polymer, which is obtained by adding a polymerizable compound to the polymerizable composition and polymerizing this composition, is irradiated with ultraviolet light. There are also provided a polymer obtained by polymerizing the polymerizable composition, and an optically anisotropic body using the polymer. The present invention provides a polymerizable low-wavelength dispersive or polymerizable reverse-wavelength dispersive compound having a partial structure represented by Formula (Z-0). Further, the present invention provides a composition containing the compound; a polymer obtained by polymerizing the composition; and an optically anisotropic body obtained by using the polymer.
Abstract:
The invention relates to antibacterial compounds formula (I) wherein R 1 is the group M, whereby M is one of the groups M A and M B represented below wherein A is a bond or C≡C; R 1A is H or halogen; R 2A is H or halogen; R 3A is H, alkoxy, hydroxyalkoxy, hydroxyalkyl, dihydroxyalkyl, 2-hydroxyacetamido, substituted cycloprop-1-yl or substituted oxetan-3-yl; and R 1B is hydroxyalkyl, dihydroxyalkyl, aminoalkyl, dialkylaminoalkyl, substituted cycloprop-1-yl, substituted cyclobutan-1-yl, substituted oxetan-3-yl, 3-hydroxythietan-3-yl, substituted azetidin-3-yl, trans -( cis -3,4-dihydroxy)-cyclopent-1-yl, 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl, 4-hydroxytetrahydro-2 H -pyran-4-yl, (3R,6S)-3-aminotetrahydro-2 H -pyran-6-yl, piperidin-4-yl or 1-(2-hydroxyacetyl)piperidin-4-yl; and salts thereof.
Abstract:
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
Abstract:
The present disclosure relates to compounds which function as small molecule fluorescent probes which aid in recognition of specific sequences in DNA and detection of Αβ aggregates. Probes/dyes of the instant disclosure are specific to AT-rich sequences of DNA and Αβ aggregates. These small organic dyes/probes are capable of exhibiting switch-on fluorescence and play an important role in fluorescence spectroscopy, diagnostics, imaging and biomedical applications.
Abstract:
Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
Abstract:
Disclosed herein are alkyl-heteroaryl substituted quinone derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.
Abstract:
The present invention relates to novel biologically active compounds being dicarboxylic acid bisamide derivatives of general formula (I), or pharmaceutically acceptable salts thereof, which are capable of complexing or chelating metal ions, and the use thereof as an agent for the prevention and/or treatment of cardiovascular, viral, cancerous, neurodegenerative and inflammatory diseases, diabetes and age-related diseases as well as diseases caused by microbial toxins, and also alcoholism, alcoholic cirrhosis, anaemia, porphyria cutanea tarda and transition metal salt poisoning. The present invention also relates to novel methods for producing dicarboxylic acid bisamide derivatives of general formula (I).